MTOR and tuberous sclerosis: Similarly, a retrospective questionnaire of direct and indirect costs of TSC in children and adolescents by Grau et al (2021) reported that mammalian target of rapamycin inhibitors, including everolimus, accounted for 46.6% of total direct costs.33